Table 1 Demographic and clinical characteristics of the overall cohort at diagnosis (all eligible patients excluding those taking CDF drugs).

From: Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry

Characteristic

Overall cohort (total)

N = 20,240

Age at diagnosis, years

 Mean (SD)

71.8 (12.3)

 Median (Q1–Q3)

73.0 (64.0–81.0)

Sex at diagnosis, n (%)

 Male

11,338 (56.0)

 Female

8,902 (44.0)

CCI, n (%)

 0*

10,147 (50.1)

 1

4,205 (20.8)

 2

2,483 (12.3)

 3

1,610 (8.0)

 4+

1,795 (8.9)

ECOG score, n (%)

 0

3,331 (16.5)

 1

2,939 (14.5)

 2

1,233 (6.1)

 3

682 (3.4)

 4+

203 (1.0)

 Missing or unknown†

11,852 (58.6)

Staging at diagnosis (ISS), n (%)

 I

2,113 (10.4)

 II

1,973 (9.8)

 III

1,944 (9.6)

 Missing or unknown†

14,210 (70.2)

Follow-up time (months), mean (SD)

32.9 (24.7)

ASCT received during follow-up, n (%)

 No

16,639 (82.2)

 Yes

3,601 (17.8)

Total number of LoTs received during follow-up

 0

8,145 (40.2)

 1

6,990 (34.5)

 2

3,127 (15.5)

 3

1,196 (5.9)

 4

472 (2.3)

 5

200 (1.0)

 6+

110 (0.5)

  1. ASCT, autologous stem cell transplantation; CCI, Charlson Comorbidity Index; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; LoT, line of therapy; Q1/Q3, quartile 1/3; SD, standard deviation.
  2. *Includes patients with poorly captured comorbidity data and patients with well-captured data but no comorbid conditions.
  3. †Missing or unknown disease stage is because staging in CAS is mainly based on TNM (tumour, node, metastasis), which is only used for solid tumours.
Back to article page